Etravirine (TMC125)CAS# 269055-15-4 |
- Ritonavir
Catalog No.:BCC3620
CAS No.:155213-67-5
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Lopinavir
Catalog No.:BCC3621
CAS No.:192725-17-0
- Atazanavir
Catalog No.:BCC3622
CAS No.:198904-31-3
- Darunavir
Catalog No.:BCC3623
CAS No.:206361-99-1
- Maraviroc
Catalog No.:BCC3675
CAS No.:376348-65-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 269055-15-4 | SDF | Download SDF |
| PubChem ID | 193962 | Appearance | Powder |
| Formula | C20H15BrN6O | M.Wt | 435.28 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | R165335; TMC125 | ||
| Solubility | DMSO : 50 mg/mL (114.87 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile | ||
| SMILES | CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N | ||
| Standard InChIKey | PYGWGZALEOIKDF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.In Vitro:TMC125 is highly active against wild-type HIV-1 (50% effective concentration [EC50]=1.4 to 4.8 nM) and shows some activity against HIV-2 (EC50=3.5 μM). TMC125 also inhibits a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. TMC125 has activity for 19 viruses with EC50 of < 5 nM[1].In Vivo:Etravirine has a high genetic barrier to the development of resistance. In phase IIb trials in treatment-experienced patients, including those infected with virus resistant to NNRTIs and protease inhibitors (PIs), TMC125 is active against HIV resistant to currently available NNRTIs, with a similar tolerability profile to that of the control group[2]. References: | |||||
Etravirine (TMC125) Dilution Calculator
Etravirine (TMC125) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2974 mL | 11.4869 mL | 22.9737 mL | 45.9474 mL | 57.4343 mL |
| 5 mM | 0.4595 mL | 2.2974 mL | 4.5947 mL | 9.1895 mL | 11.4869 mL |
| 10 mM | 0.2297 mL | 1.1487 mL | 2.2974 mL | 4.5947 mL | 5.7434 mL |
| 50 mM | 0.0459 mL | 0.2297 mL | 0.4595 mL | 0.9189 mL | 1.1487 mL |
| 100 mM | 0.023 mL | 0.1149 mL | 0.2297 mL | 0.4595 mL | 0.5743 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.
- 2(-4-Chloro-3-hydroxy-1-butynyl)-5-1,(3-pentadiynyl)thiophene
Catalog No.:BCN1465
CAS No.:26905-70-4
- Oxysophocarpine
Catalog No.:BCN5156
CAS No.:26904-64-3
- 6-Hydroxybenzofuran-2(3H)-one
Catalog No.:BCN5155
CAS No.:2688-49-5
- Isomahanimbine
Catalog No.:BCN3175
CAS No.:26871-46-5
- 1,3-Bis[2-(4-aminophenyl)-2-propyl]benzene
Catalog No.:BCC8419
CAS No.:2687-27-6
- Penfluridol
Catalog No.:BCC4696
CAS No.:26864-56-2
- Triptohypol F
Catalog No.:BCN5154
CAS No.:268541-26-0
- Homoharringtonine
Catalog No.:BCN4958
CAS No.:26833-87-4
- Harringtonine
Catalog No.:BCN6794
CAS No.:26833-85-2
- Coronalolic acid
Catalog No.:BCN5153
CAS No.:268214-52-4
- Coronalolide
Catalog No.:BCN5152
CAS No.:268214-51-3
- Coronalolide methyl ester
Catalog No.:BCN5151
CAS No.:268214-50-2
- Fmoc-Orn(Dde)-OH
Catalog No.:BCC3534
CAS No.:269062-80-8
- H-D-Dab-OH.2HCl
Catalog No.:BCC3185
CAS No.:26908-94-1
- Timolol Maleate
Catalog No.:BCC4340
CAS No.:26921-17-5
- Aglaxiflorin D
Catalog No.:BCN6594
CAS No.:269739-78-8
- 16-Acetoxy-7-O-acetylhorminone
Catalog No.:BCN5157
CAS No.:269742-39-4
- Sphingosine-1-phosphate
Catalog No.:BCC7034
CAS No.:26993-30-6
- Lariciresinol
Catalog No.:BCN5158
CAS No.:27003-73-2
- 3,4-Dichloro-Phe-OMe.HCl
Catalog No.:BCC2635
CAS No.:270063-47-3
- 17-Hydroxy-1a,2a-methylenepregna-4,6-diene-3,20-dione acetate
Catalog No.:BCC8442
CAS No.:2701-50-0
- alpha-Hederin
Catalog No.:BCN5159
CAS No.:27013-91-8
- 2'-Methoxykurarinone
Catalog No.:BCN2986
CAS No.:270249-38-2
- H-D-Glu(OMe)-OMe.HCl
Catalog No.:BCC2941
CAS No.:27025-25-8
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).[Pubmed:20236364]
HIV Med. 2010 Sep;11(8):530-4.
OBJECTIVES: To evaluate whether Etravirine (TMC125) might be effective in patients failing therapy with current nonnucleoside reverse transcriptase inhibitors (NNRTIs), we analysed the prevalence of TMC125 mutations and the possible determinants of genotypic resistance to this drug among sequences reported to a large database in Italy [Antiretroviral Resistance Cohort Analysis (ARCA)]. METHODS: We analysed the prevalence of TMC125 resistance-associated mutations (RAMs) and the TMC125 weighted genotypic score (WGS) together with the determinants of genotypic resistance. A total of 5011 sequences from 2955 patients failing NNRTI therapy were evaluated. RESULTS: Among the sequences in ARCA, 68% had at least one and 9.8% at least three TMC125 RAMs, whereas 31% had a WGS>2. Frequent RAMs were Y181C, G190A, K101E and A98G, whereas V179F, Y181V and G190S appeared in <5% of sequences. Multivariate analysis revealed a higher risk of developing at least three TMC125 RAMs associated with both nevirapine and efavirenz exposure, whereas CD4 counts > or = 200 cells/microL retained their protective effect. An increased risk of WGS>2 was linked to higher HIV RNA values (maximum risk at >5 log(10) copies/mL) and nevirapine exposure; CD4 counts > or = 200 cells/microL were protective. CONCLUSIONS: The prevalence of TMC125 resistance mutations in the ARCA cohort was 68%. The DUET studies showed that at least three TMC125-associated mutations were required to impair the efficacy of the drug and Y181C/V, V179F and G190S had the greatest effect on response. The prevalence of these mutations among the patients examined in our study was low. However, WGS>2 was found for one-third of our sequences. Previous nevirapine exposure was associated with an increased risk of having WGS>2 (adjusted odds ratio 1.76).
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.[Pubmed:20438081]
J Med Chem. 2010 May 27;53(10):4295-9.
Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain activity against a wide range of resistance mutations. Crystal structures were determined with wild-type and K103N HIV-1 reverse transcriptase with Etravirine (TMC125) and rilpivirine (TMC278). These structures reveal a similar binding mode for TMC125 and TMC278, whether bound to wild-type or K103N RT. Comparison to previously published structures reveals differences in binding modes for TMC125 and differences in protein conformation for TMC278.
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.[Pubmed:19114852]
AIDS. 2009 Jan 28;23(3):423-6.
Forty-eight-week results from a randomized, multicentre, part-blinded, phase IIb clinical trial assessing the efficacy and safety of 400 and 800 mg etravirine twice daily (phase IIb formulation) and optimized background regimen versus standard-of-care regimen are presented. Both etravirine doses demonstrated sustained virological suppression at 48 weeks and a favourable tolerability profile. Etravirine demonstrated higher efficacy than control, irrespective of the number of detectable nonnucleoside reverse transcriptase inhibitor-resistance-associated mutations at baseline or active background antiretrovirals.
Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.[Pubmed:19059744]
J Pharm Biomed Anal. 2009 Feb 20;49(2):393-400.
For the quantification of the novel non-nucleoside reverse transcriptase inhibitor etravirine in human plasma, dried blood spots and peripheral blood mononuclear cell (PBMC) lysate, an assay was developed and validated, using liquid chromatography coupled with tandem mass spectrometry. Etravirine was extracted from plasma by means of protein precipitation with a mixture of methanol and acetonitrile using only 50 microL plasma. Extraction from dried blood spots was performed with a one-step extraction with a mixture of methanol, acetonitrile and 0.2M zinc sulphate in water (1:1:2, v/v/v) and extraction from cell lysate was performed in 50% methanol in water. Chromatographic separation was performed on a reversed phase C18 column (150mmx2.0mm, particle size 5microm) with a quick stepwise gradient using an acetate buffer (pH 5) and methanol, at a flow rate of 0.25mL/min. (13)C(6)-efavirenz was used as an internal standard. The analytical run time was only 10min. The triple quadrupole mass spectrometer was operated in the positive ion-mode and multiple reaction monitoring was used for drug quantification. The method was validated over a range of 25-5000ng/mL in plasma, 50-10,000ng/mL in dried blood spots and a range of 5-2500ng/mL in PBMC lysate. Accuracies ranged from 89% to 106% in plasma, from 94% to 109% in dried blood spots and from 91% to 105% in PBMC lysate. Precisions at the all concentration levels ranged from 1.9% to 14% in plasma, 4.7% to 20% in dried blood spots and from 3.1% to 11% in PBMC lysate. The bioanalytical assay was successfully incorporated with previously developed assays for the determination of all currently approved PIs and NNRTIs in plasma and dried blood spots and it is now applied for therapeutic drug monitoring and pharmacological research in HIV-infected patients treated with etravirine.
